Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05097664

Enrollment

250

Registered

2021-10-28

Start date

2021-08-23

Completion date

2022-01-20

Last updated

2021-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Mucormycosis

Keywords

Coronavirus Disease-Associated Mucormycosis, COVID-19, Rhino-orbital-cerebral mucormycosis, Mucormycosis

Brief summary

Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

Detailed description

Investigators will achieved the following data from the participants: 1. Demographic 2. Past medical/habitual history 3. COVID-19 status and related risk factors 4. Mucormycosis status and related risk factors 5. Ocular examination and imaging 6. Follow-up

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosed case of Mucormycosis in COVID-19 pandemic

Exclusion criteria

* People with acute or severely ill conditions that prevent them from ophthalmic examination. * Patient, or legal representative opposing the pursuit of the research

Design outcomes

Primary

Measure	Time frame	Description
Vision loss	3 months	Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection

Secondary

Measure	Time frame	Description
Risk factors	3 months	Related risk factors for vision loss

Countries

Iran

Contacts

Primary ContactMohsen Pourazizi, M.D.

m.pourazizi@med.mui.ac.ir00983134452036

Outcome results